Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Real-world study of fast-acting insulin aspart

Type 1 diabetes – November 2020 digest

Real-world results demonstrate improved glycaemic control via reduced hyperglycaemia, without any changes in basal insulin or mean insulin dose, in users who switch their bolus insulin to fast-acting aspart.

This single-arm, observational, non-interventional study assessed the effectiveness and safety of fast-acting insulin aspart (Novo Nordisk’s Fiasp) in a real-world cohort of people with type 1 diabetes in Germany. A total of 241 adults with type 1 diabetes on multiple daily injections who switched their bolus insulin to fast aspart and who were established users of flash glucose monitoring were followed up at treatment initiation and 12 and 24 weeks thereafter.

Over the follow-up, mean HbA1c fell significantly, from 64.8 to 62.8 mmol/mol, while postprandial glucose levels fell by 0.8 mmol/L. Among the 92 participants who had sufficient glucose monitoring data, time in range increased from 46.9% to 50.1% at the final follow-up. This was driven by a reduction in time spent in hyperglycaemia, while hypoglycaemia rates were unchanged. Safety analysis of the whole cohort did not reveal any unexpected findings.

The authors conclude that these real-world results reflected the findings in the ONSET phase 3 clinical trials of fast-acting aspart, highlighting the improved glycaemic control via reduced hyperglycaemia, without any changes in basal insulin or mean insulin dose.

Danne T, Schweitzer MA, Keuthage W et al (2020) Impact of fast-acting insulin aspart on glycemic control in patients with type 1 diabetes using intermittent-scanning continuous glucose monitoring within a real-world setting: the GoBolus study. Diabetes Technol Ther 21 Oct [epub ahead of print]. https://doi.org/10.1089/dia.2020.0360

Click here for all this month’s Digests.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.